Treating patients with renal cell carcinoma and bone metastases

References

• Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
   Google Scholar
• Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973–980.
   PubMed Web of Science ®Google Scholar
• K. Hernandez, Rohini & Wade, Sally & Reich, et al. Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer. 2018;18(1):44.
   Google Scholar
• Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011;48:160–166.
   PubMed Web of Science ®Google Scholar
• Santini D, Procopio G, Porta C, et al. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLoS One. 2013;8:e83026.
   PubMed Web of Science ®Google Scholar
• Santoni M, Conti A, Procopio G, et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. J Exp Clin Cancer Res. 2015;34(1):10.
   PubMedGoogle Scholar
• McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65:577–584.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108:2470–2477.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2011;22:794–800.
   PubMed Web of Science ®Google Scholar
• Kalra S, Verma J, Atkinson BJ, et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer. 2017;15:363–370.
   PubMed Web of Science ®Google Scholar
• Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011;22:295–300.
   PubMed Web of Science ®Google Scholar
• McKay RR, Lin X, Perkins JJ, et al. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol. 2014;66:502–509.
   PubMedGoogle Scholar
• Plimack ER, Tannir N, Lin E, et al. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009;115:1859–1866.
   PubMed Web of Science ®Google Scholar
• Vrdoljak E, Gore M, Leyman S, et al. Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis. Future Oncol. 2015;11:2831–2840.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814–1823.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–927.
   PubMed Web of Science ®Google Scholar
• Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? subgroup analysis of the METEOR trial. J Clin Oncol. 2018;36:765–772.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35:591–597.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:962–971.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018.
   Web of Science ®Google Scholar
• Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer. 2002;1:145–152.
   PubMedGoogle Scholar
• Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol. 2002;29:19–27.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol. 2003;21:3150–3157.
   PubMed Web of Science ®Google Scholar
• Lipton A, Zheng M. Seaman J Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962–969.
   PubMed Web of Science ®Google Scholar
• Vrdoljak E, Geczi L, Mardiak J, et al. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial. Pathol Oncol Res. 2015;21:775–782.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Wolter P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012;107:1665–1671.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Pili R, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer. 2012;48:1031–1037.
   PubMed Web of Science ®Google Scholar
• Broom RJ, Hinder V, Sharples K, et al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial. Clin Genitourin Cancer. 2015;13:50–58.
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25:4431–4437.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–1571.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–5139.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–822.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–1132.
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2016;53:75–83.
   PubMed Web of Science ®Google Scholar
• Bossé DMR, Gray KP, Michaelson MD, et al. Pazopanib or sorafenib + radium-223 in metastatic renal cell carcinoma with bone metastases. Ann Oncol. 2017;28(suppl_5):v295–v329.
   Google Scholar
• Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873–2882.
   PubMed Web of Science ®Google Scholar
• Ratasvuori M, Wedin R, Hansen BH, et al. Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. J Surg Oncol. 2014;110:360–365.
   PubMed Web of Science ®Google Scholar
• Daliani DD, Tannir NM, Papandreou CN, et al. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int. 2009;104:456–460.
   PubMed Web of Science ®Google Scholar
• Fottner A, Szalantzy M, Wirthmann L, et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord. 2010;11(145).
   PubMedGoogle Scholar
• Laitinen A, Oja S, Kilpinen L, et al. A robust and reproducible animal serum-free culture method for clinical-grade bone marrow-derived mesenchymal stromal cells. Cytotechnology. 2016;68:891–906.
   PubMed Web of Science ®Google Scholar
• Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89:1794–1801.
   PubMed Web of Science ®Google Scholar
• Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7:44–54.
   PubMed Web of Science ®Google Scholar
• Lo SS, Teh BS, Mayr NA, et al. Stereotactic body radiation therapy for oligometastases. Discov Med. 2010;10:247–254.
   PubMed Web of Science ®Google Scholar
• Svedman C, Sandstrom P, Pisa P, et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870–875.
   PubMed Web of Science ®Google Scholar
• Amini A, Altoos B, Bourlon MT, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant? Pract Radiat Oncol. 2015;5:e589–e596.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Greco C, Motzer R, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:1744–1748.
   PubMed Web of Science ®Google Scholar
• Nguyen QN, Shiu AS, Rhines LD, et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010;76:1185–1192.
   PubMed Web of Science ®Google Scholar
• Balagamwala EH, Angelov L, Koyfman SA, et al. Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma. J Neurosurg Spine. 2012;17:556–564.
   PubMed Web of Science ®Google Scholar
• Deschamps F, Farouil G, Ternes N, et al. Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol. 2014;24:1971–1980.
   PubMed Web of Science ®Google Scholar
• Welch BT, Callstrom MR, Morris JM, et al. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol. 2014;192:357–363.
   PubMed Web of Science ®Google Scholar
• McMenomy BP, Kurup AN, Johnson GB, et al. Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. J Vasc Interv Radiol. 2013;24:207–213.
   PubMed Web of Science ®Google Scholar
• Bang HJ, Littrup PJ, Goodrich DJ, et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol. 2012;23:770–777.
   PubMed Web of Science ®Google Scholar
• Lee JK, Seki N, Sayers TJ, et al. Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol. 2005;235:145–152.
   PubMed Web of Science ®Google Scholar
• Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112–124.
   PubMed Web of Science ®Google Scholar
• Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol. 2000;164:1505–1508.
   PubMed Web of Science ®Google Scholar
• Dupuy DE, Liu D, Hartfeil D, et al. Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of radiology imaging network trial. Cancer. 2010;116:989–997.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Callstrom MR, Charboneau JW, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004;22:300–306.
   PubMed Web of Science ®Google Scholar
• Callstrom MR, Dupuy DE, Solomon SB, et al. Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial. Cancer. 2013;119:1033–1041.
   PubMed Web of Science ®Google Scholar
• Prologo JD, Passalacqua M, Patel I, et al. Image-guided cryoablation for the treatment of painful musculoskeletal metastatic disease: a single-center experience. Skeletal Radiol. 2014;43:1551–1559.
   PubMed Web of Science ®Google Scholar
• Munk PL, Rashid F, Heran MK, et al. Combined cementoplasty and radiofrequency ablation in the treatment of painful neoplastic lesions of bone. J Vasc Interv Radiol. 2009;20:903–911.
   PubMed Web of Science ®Google Scholar
• Toyota N, Naito A, Kakizawa H, et al. Radiofrequency ablation therapy combined with cementoplasty for painful bone metastases: initial experience. Cardiovasc Intervent Radiol. 2005;28:578–583.
   PubMed Web of Science ®Google Scholar
• Pellerin O, Medioni J, Vulser C, et al. Management of painful pelvic bone metastasis of renal cell carcinoma using embolization, radio-frequency ablation, and cementoplasty: a prospective evaluation of efficacy and safety. Cardiovasc Intervent Radiol. 2014;37:730–736.
   PubMed Web of Science ®Google Scholar
• Ward WG, Holsenbeck S, Dorey FJ, et al. Metastatic disease of the femur: surgical treatment. Clin Orthop Relat Res. 2003;S230-244.
   Google Scholar
• Ristevski B, Jenkinson RJ, Stephen DJ, et al. Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can J Surg. 2009;52:302–308.
   PubMed Web of Science ®Google Scholar